Category Archive: As I See It

Pharma still blaming drug middlemen for obscene prices

  • Pharma, which used to cite the high cost of research, now say rebates within supply chain drive up prices.
  • Pharma says they don’t actually benefit much from list-price increases and that their net prices are suffering, because they are paying bigger rebates to pharmacy-benefit managers that negotiate prices in secret with their clients, such as employers and labor unions.
  • Drugmakers’ price increases are unrelated to the rebates, according to research commissioned by the Pharmaceutical Care Management Association, a trade group for PBMs.
Continue reading →

Pharma and McKinsey: A devil’s​ match

  • McKinsey & Company, according to the Massachusetts AG, had helped the maker of OxyContin fan the flames of the opioid epidemic.
  • McKinsey’s consultants, the attorney general revealed, had instructed the drug company, Purdue Pharma, on how to “turbocharge” sales of OxyContin.
  • McKinsey had advised numerous pharma clients to raise prices on cancer and rare disease drugs because “insurance would pay the high prices”.
Continue reading →

The difference between “willing to “and actually will” is enormous

  • Fifty-four percent of consumers are willing to try an FDA-approved app or digital tool for the treatment of a medical condition, according to a new report out of PricewaterhouseCoopers
  • A fall PwC’s survey of 1,750 US adults also found that doctors are suggesting digital tools to patients more often, with 77 percent of doctors have recommended an app or digital program to their patients.
  • As these technologies begin to become more mainstreamed, validation has also become a hot topic.
Continue reading →

Media irresponsibility

KEY TAKEAWAY: There is nothing worse than promising very sick or dying patients with false hope of a “miracle cure”. Yet, Forbes and other media outlets, like The Hill, have spread the story about a small team of Israeli scientists who are telling the world they will have the first “complete cure” for cancer within a year. And not only that, but they claim it will be brief, cheap and effective and will have no or minimal side-effects. This company is another Theranos?

Continue reading →

The healthcare debate the media refuses to acknowledge

  • Drug prices continue to fuel media stories and drive politicians to action but, for the most part, the real driver of high healthcare costs is being ignored.
  • The total percentage of non-elderly people with insurance and affordability problems to 26.2%.
  • The number of US adults with diabetes increased from 21.2 million in 2003-2004 to 30.2 million in 2013-2014, while the prevalence of obesity rose from 31.7% to 37.5% over the same period.
  • Millennials are on track to be the most obese generation.
Continue reading →